US · ADXN
Addex Therapeutics Ltd
- Sector
- Healthcare · Biotechnology
- Headquarters
- Geneva 1202
- Website
- addextherapeutics.com
Price · as of 2024-12-31
$7.00
Market cap 4.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $859.50 | +12,178.57% |
| Intrinsic Value(DCF) | $10.06 | +43.71% |
| Graham-Dodd Method(GD) | $68.80 | +882.86% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $212,252.70 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $42,183.30 | |||
| 2013 | $0.00 | $3,597.80 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $2,465.60 | |||
| 2016 | $0.00 | $1,922.80 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $200.00 | $0.00 | |||
| 2019 | $226.00 | $50,643.67 | $202,684.70 | $0.00 | $3,671.80 |
| 2020 | $215.80 | $133.96 | $33,620.64 | $0.00 | $0.00 |
| 2021 | $103.60 | $41.44 | $161.17 | $0.00 | $691.60 |
| 2022 | $25.20 | $10.08 | $23.30 | $0.00 | $2,824.40 |
| 2023 | $11.50 | $1,116.39 | $26.97 | $0.00 | $0.00 |
| 2024 | $7.70 | $686.74 | $12.01 | $68.80 | $0.00 |
AI valuation
Our deep-learning model estimates Addex Therapeutics Ltd's (ADXN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $859.50
- Current price
- $7.00
- AI upside
- +12,178.57%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.06
+43.71% upside
Graham-Dodd
$68.80
+882.86% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADXN | Addex Therapeutics Ltd | $7.00 | 4.81M | +9,711% | +44% | +883% | — | 0.71 | 0.52 | 12.45 | -0.37 | — | 0.52 | 100.00% | -681.82% | 1746.04% | 130.39% | -137.95% | 92.11% | 0.00 | -776.78 | 4.42 | 4.19 | 0.71 | -15000.00% | -7495.00% | -3281.00% | -106.85% | -6.70 | -269.11% | 0.00% | 0.00% | 0.00% | -0.63 | -0.32 | 4.27 | -43.82 |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| CDIO | Cardio Diagnostics Holdin… | $6.55 | 11.96M | +576% | -17% | — | — | -43.50 | 38.15 | 10451.97 | -44.24 | — | 41.20 | 100.00% | -23977.86% | -24028.24% | -133.96% | -296.88% | -111.20% | 0.10 | -448.81 | 13.92 | 12.42 | 0.85 | -5303.00% | 10445.00% | -1653.00% | -1.48% | -7.90 | -191.54% | 0.00% | 0.00% | 1.87% | -42.77 | -66.29 | 10255.42 | 202.22 |
| NRSN | NeuroSense Therapeutics L… | $0.91 | 22.42M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
- CEO
- Timothy Mark Dyer
- Employees
- 2
- Beta
- 1.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.06 ÷ $7.00) − 1 = +43.71% (DCF, example).